GlassScriptPhysician profile
Lara J Fix
NPI 1043263924
$20,399.24
in general payments reported to CMS, 2019-2025
63 companies · $3,032 in 2025
The $3,032 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,306 · 2020: $1,994 · 2021: $2,865 · 2022: $3,464 · 2023: $3,160 · 2024: $3,579 · 2025: $3,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,580 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,579.80 |
| Education | $191.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,166.33 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Ucb, INC. | $2,061.04 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,268.25 | 2019-2025 | |
| Abbvie INC. | $1,250.72 | 2021-2025 | |
| Lilly USA, LLC | $1,114.58 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $977.08 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $868.63 | 2023-2025 | |
| Lundbeck LLC | $674.74 | 2019-2025 | Rexulti, Vyepti |
| Eisai INC. | $658.67 | 2023-2025 | |
| Emd Serono, INC. | $657.27 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $617.90 | 2019-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $507.36 | 2019-2022 | |
| Genzyme Corporation | $504.86 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $427.10 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Otsuka America Pharmaceutical, INC. | $397.11 | 2023-2025 | Rexulti, Nuedexta |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $350.22 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $337.21 | 2019-2025 | Uplizna |
| Sk Life Science, INC. | $332.96 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $311.40 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $308.09 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $305.15 | 2021-2024 | Ultomiris, Soliris |
| Mdd US Operations, LLC | $277.01 | 2022-2025 | Apokyn, Apokyn, Gocovri |
| Avanir Pharmaceuticals, INC. | $269.03 | 2019-2022 | |
| Celgene Corporation | $246.52 | 2021-2024 | Zeposia |
| Tanabe Pharma America, INC. | $246.25 | 2020-2025 | Radicava |
| Kyowa Kirin, INC. | $238.07 | 2020-2024 | Nourianz |
| Acorda Therapeutics, INC | $236.79 | 2019-2024 | Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $236.50 | 2022 | |
| Csl Behring | $229.90 | 2019-2023 | Hizentra, Privigen |
| Allergan, INC. | $177.38 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $161.95 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $156.82 | 2020-2021 | |
| Grifols USA, LLC | $153.03 | 2020-2025 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $144.82 | 2021-2023 | Ponvory |
| Vanda Pharmaceuticals INC. | $98.14 | 2024-2025 | Ponvory |
| Neurelis, INC. | $95.67 | 2020-2025 | Valtoco |
| Axsome Therapeutics, INC. | $88.12 | 2025 | Symbravo |
| Avion Pharmaceuticals | $85.11 | 2022-2023 | Dhivy |
| Sumitomo Pharma America, INC. | $83.55 | 2023 | Aptiom |
| Livanova USA, INC. | $82.04 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Greenwich Biosciences, INC. | $81.35 | 2019 | |
| Ge Healthcare | $79.53 | 2019 | |
| Acadia Pharmaceuticals INC | $75.78 | 2019-2022 | |
| Zyla Life Sciences, INC. | $74.75 | 2020 | |
| Arbor Pharmaceuticals, INC. | $65.02 | 2019-2022 | |
| Harmony Biosciences LLC | $58.82 | 2021 | |
| Ani Pharmaceuticals, INC. | $58.38 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $53.79 | 2020-2021 | |
| Alfasigma USA, INC. | $46.60 | 2020-2021 | |
| C2n Diagnostics, LLC | $45.55 | 2025 | Precivityad2 |
| Abbott Laboratories | $41.25 | 2021 | |
| Genentech USA, INC. | $36.00 | 2019-2024 | Ocrevus |
| Bausch Health US, LLC | $35.57 | 2019 | |
| Corium, LLC | $34.37 | 2023 | Adlarity |
| Tg Therapeutics, INC. | $34.00 | 2025 | |
| Impel Pharmaceuticals INC. | $31.69 | 2022-2023 | Trudhesa |
| Nevro Corp. | $26.71 | 2023 | Senza |
| Astrazeneca Pharmaceuticals LP | $24.54 | 2022 | |
| Mallinckrodt Hospital Products INC. | $22.90 | 2022 | |
| Life Molecular Imaging LTD | $20.07 | 2025 | Neuraceq |
| Xeris Pharmaceuticals, INC. | $19.22 | 2025 | Keveyis |
| Merz Pharmaceuticals, LLC | $17.76 | 2025 | Inbrija |
| Vertical Pharmaceuticals, LLC | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Fix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.